Carbon nanotubes (CNTs) have emerged as promising nanomaterials with unique properties that hold great potential in the pharmaceutical field. These cylindrical structures, composed of rolled-up graphene sheets, exhibit exceptional mechanical strength, electrical conductivity, and a high surface area, making them versatile candidates for various applications. In the realm of pharmaceuticals, carbon nanotubes offer novel opportunities for drug delivery systems, diagnostic imaging, and therapeutic interventions. Their hollow structures can be utilized to encapsulate drugs, protecting them from degradation and facilitating controlled release. Furthermore, the high aspect ratio and surface functionalization potential of CNTs enable targeted drug delivery to specific cells or tissues, minimizing off-target effects.
Carbon nanotubes also exhibit excellent biocompatibility and can be engineered to carry diagnostic agents for imaging purposes, aiding in the early detection of diseases. Additionally, their unique electronic properties have led to advancements in biosensor development, offering sensitive and rapid detection of biomolecules. Despite the significant promise, challenges such as biocompatibility, toxicity, and large-scale production need to be addressed to fully harness the potential of carbon nanotubes in the pharmaceutical field. Ongoing research continues to explore and optimize the applications of CNTs, paving the way for innovative solutions in drug delivery and diagnostics.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia